ISMETT Accredited for 3rd Time By Joint Commission International
PITTSBURGH, Nov. 20, 2015 –ISMETT, a leading Italian transplant hospital managed by UPMC, has been accredited for the third time by Joint Commission International (JCI), the organization that certifies the safety and quality of care provided to patients in hospitals around the world.
The re-accreditation followed a rigorous, four-day assessment at ISMETT that included evaluation of its compliance with more than 300 standards of care. JCI focuses on determining whether a health care facility has the right systems and processes in place to support high-quality and safe patient care and has the culture and capacity to continuously improve care. Its surveyors examine crucial issues such as the safe use of medications, infection prevention and control, patient assessment and patient rights.
In 2010, ISMETT was the first hospital in southern Italy to voluntarily receive JCI accreditation. It was re-accredited in 2012 and again last month.
"The results of JCI's rigorous survey are further confirmation that ISMETT makes effective use of the resources supplied by the regional government to provide the highest-quality care to our patients,” said Bruno Gridelli, M.D., chief executive officer of ISMETT. “ISMETT and UPMC Italy staff should be commended for creating an environment that puts the health and safety of our patients at the center of everything we do.”
Formally known as the Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, ISMETT has performed more than 1,600 transplants since it began operations in 1999 and tens of thousands of high specialty procedures, including cardiothoracic and cancer surgeries. An example of innovative and efficient clinical management, ISMETT is a public-private partnership between UPMC and the Region of Sicily, through ARNAS Civico hospital in Palermo. ISMETT is the only hospital in Italy designed and intended exclusively for solid organ transplantation and highly specialized therapies. It boasts patient survival rates that are among the best in Europe and treats more than 30,000 patients a year with severe organ disease.